Drug Price Trends for VYVANSE

Average Pharmacy Cost for VYVANSE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VYVANSE 10 MG CAPSULE	59417-0101-10	12.37916	EACH	2025-03-19
VYVANSE 10 MG CHEWABLE TABLET	59417-0115-01	12.38560	EACH	2025-03-19
VYVANSE 20 MG CHEWABLE TABLET	59417-0116-01	12.38931	EACH	2025-03-19
VYVANSE 20 MG CAPSULE	59417-0102-10	12.38462	EACH	2025-03-19

Market Analysis and Price Projections for Vyvanse

Introduction to Vyvanse

Vyvanse, also known as lisdexamfetamine dimesylate, is a prescription medication primarily used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and binge-eating disorder. Developed by Shire and later acquired by Takeda in 2019, Vyvanse has been a significant player in the ADHD market since its FDA approval in 2007.

Current Market Position

As of 2022, Vyvanse held the largest market share among branded ADHD products, generating approximately $2.5 billion in sales across the US, Japan, Germany, Spain, and the UK[1].

Patent Expiry and Generic Competition

A critical turning point for Vyvanse was the expiry of its US patent in August 2023. This event marked the beginning of generic competition, with the FDA approving multiple generic versions of the drug from manufacturers such as Teva, Sun Pharmaceutical, Actavis, Mylan, and Hikma[3].

Despite the patent expiry, the uptake of generic versions has been slower than expected due to manufacturing delays and shortages of active pharmaceutical ingredients (APIs). These shortages have affected the supply of both branded and generic Vyvanse, leading to a milder-than-anticipated market-share erosion for the branded product[4].

Impact on Takeda's Financials

The loss of exclusivity for Vyvanse has had a significant impact on Takeda's financial performance. In the first nine months of Takeda's 2023 fiscal year, Vyvanse sales fell by 12.1% to 312.9 billion yen ($2.14 billion), which was in line with expectations given the generic competition[4].

Takeda's overall revenue for the fiscal year remained flat at constant exchange rates, but the company's net profit and operating profit saw substantial declines. The net profit dropped by 57%, and the operating profit fell by 50.3% due to increased operating expenses and impairments related to other products[5].

Price Dynamics

The cost of Vyvanse has been a significant factor for patients. A 100-day supply of the branded drug can cost around $1,305, with prices varying slightly depending on the pharmacy and dosage form. For example, a 100-capsule supply of Vyvanse can cost approximately $1,370.62, with a per-unit price of around $13.71[2].

The introduction of generics is expected to reduce the cost burden on patients. However, the current shortages and supply constraints have limited the immediate impact of generic competition on pricing.

Future Projections

Sales Erosion

GlobalData predicts that the API shortages affecting generic Vyvanse will be resolved by 2027, leading to a return to normal generic uptake levels. This will result in significant sales erosion for the branded product, further impacting Takeda's revenue[1].

Market Forecast

The ADHD market, including Vyvanse, is forecasted to decline by $1 billion between 2022 and 2032. This decline is largely attributed to the increased competition from generics and the resolution of current supply shortages[1].

Takeda's Strategic Response

To counter the loss of exclusivity and subsequent sales decline, Takeda is focusing on its newer products and pipeline developments. The company aims to return to sales, profit, and margin growth in the near term (fiscal years 2024-2025) and plans to expand the reach of its new medicines in the medium term[4].

Takeda is also implementing an enterprise-wide efficiency program starting in fiscal year 2024, aimed at improving operational efficiency at a projected cost of nearly $900 million[5].

Key Takeaways

• Patent Expiry and Generic Competition: The expiry of Vyvanse's US patent in August 2023 has led to the approval of multiple generic versions, although their uptake is currently limited by API shortages.
• Financial Impact: The loss of exclusivity has resulted in a significant decline in Vyvanse sales and Takeda's overall financial performance.
• Price Dynamics: The introduction of generics is expected to reduce costs for patients, but current shortages are limiting the immediate price impact.
• Future Projections: The ADHD market, including Vyvanse, is forecasted to decline, with significant sales erosion expected for the branded product once API shortages are resolved.
• Takeda's Strategic Response: Takeda is focusing on newer products, pipeline developments, and operational efficiency to mitigate the impact of generic competition.

FAQs

1. What is the current market position of Vyvanse?

   • As of 2022, Vyvanse held the largest market share among branded ADHD products, generating approximately $2.5 billion in sales across key markets[1].

2. What happened to Vyvanse's patent?

   • Vyvanse's US patent expired in August 2023, allowing for the approval and launch of generic versions[3].

3. Why is the uptake of generic Vyvanse slower than expected?

   • The uptake is slower due to manufacturing delays and shortages of active pharmaceutical ingredients (APIs)[4].

4. How has the loss of exclusivity affected Takeda's financials?

   • The loss of exclusivity has led to a significant decline in Vyvanse sales and a substantial drop in Takeda's net profit and operating profit[5].

5. What is Takeda's strategy to counter the impact of generic competition?

   • Takeda is focusing on newer products, pipeline developments, and implementing an enterprise-wide efficiency program to improve operational efficiency[4][5].

Sources

1. Clinical Trials Arena: "ADHD market forecast to decline by $1bn between 2022 and 2032"[1]
2. Drugs.com: "Vyvanse Prices, Coupons, Copay Cards & Patient Assistance"[2]
3. Fierce Pharma: "Generic Vyvanse cleared by FDA Amid shortage"[3]
4. Fierce Pharma: "Takeda treads water despite loss of exclusivity on Vyvanse"[4]
5. Synapse: "Takeda Lowers Profit Forecast Amid Vyvanse Exclusivity Loss Plans $900m Restructuring in 2024"[5]